

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6862282

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CURIA GLOBAL, INC. (F/K/A ALBANY MOLECULAR RESEARCH, INC.)	08/04/2021
RECEIVING PARTY DATA	
Name:	HARMONY BIOSCIENCES, LLC
Street Address:	630 W. GERMANTOWN PIKE
Internal Address:	SUITE 215
City:	PLYMOUTH MEETING
State/Country:	PENNSYLVANIA
Postal Code:	19462
PROPERTY NUMBERS Total: 6	
Property Type	Number
Application Number:	61020530
Application Number:	61048677
PCT Number:	US2009030646
Application Number:	12351561
Application Number:	14223151
Application Number:	15045652
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6786941262
Email:	docket@kipsllc.com
Correspondent Name:	KNOWLES INTELLECTUAL PROPERTY STRATEGIES, LLC
Address Line 1:	400 PERIMETER CENTER TERRACE
Address Line 2:	SUITE 200
Address Line 4:	ATLANTA, GEORGIA 30346
ATTORNEY DOCKET NUMBER:	20102-009
NAME OF SUBMITTER:	BRENT R. BELLOWS
SIGNATURE:	/Brent R. Bellows/
DATE SIGNED:	08/12/2021

PATENT

Total Attachments: 7

source=20102-009 - Piano - 646 Executed PCT Assignment#page1.tif

source=20102-009 - Piano - 646 Executed PCT Assignment#page2.tif

source=20102-009 - Piano - 646 Executed PCT Assignment#page3.tif

source=20102-009 - Piano - 646 Executed PCT Assignment#page4.tif

source=20102-009 - Piano - 646 Executed PCT Assignment#page5.tif

source=20102-009 - Piano - 646 Executed PCT Assignment#page6.tif

source=20102-009 - Piano - 646 Executed PCT Assignment#page7.tif

ASSIGNMENT

WHEREAS, **CURIA GLOBAL, INC. (F/K/A ALBANY MOLECULAR RESEARCH, INC.)** a Delaware corporation, (hereinafter "ASSIGNOR"), owns certain inventions and improvements related to (1-azinone)-substituted pyridoindoles disclosed in United States provisional patent applications identified in Annex A (collectively, the "Priority Documents") and in international and United States patents claiming priority to the Priority Documents including those listed in Annex B (collectively, the "Patents/Applications").

WHEREAS, **HARMONY BIOSCIENCES, LLC** ("ASSIGNEE"), a business entity organized and existing under the laws of the state of Delaware, desires to acquire the ownership of, the entire right, title, and interest in and to said inventions, improvements, know-how, Patents/Applications, and Priority Documents, and in and to any additional Letters Patents which may have or may be granted therefrom.

NOW, THEREFORE, ASSIGNOR assigns the inventions disclosed in the Patents/Applications and Priority Documents to ASSIGNEE, for good and valuable consideration previously paid to ASSIGNOR, the receipt and sufficiency of which is hereby acknowledged, and ASSIGNOR by these presents hereby does sell, assign, and transfer, to ASSIGNEE the full, exclusive, and entire right, title, and interest in and to said Patents/Applications, Priority Documents, and in and to all inventions and improvements disclosed and described in said Patents/Applications and Priority Documents, as well as all know-how derived during the development of, and directed to, the inventions and improvements disclosed and described in said Patents/Applications and Priority Documents, and any additional Letters Patents that may have or will grant therefrom.

For the same consideration, ASSIGNOR, by these presents, does sell, assign, and transfer, to ASSIGNEE the full, exclusive, and entire right to claim priority to said Patents/Applications and/or Priority Documents, in whole or in part, arising from or required under the terms of any applicable conventions, treaties, statutes, or regulations.


For the same consideration, ASSIGNOR, by these presents, does sell, assign, and transfer, to ASSIGNEE the full, exclusive, and entire right, title, and interest in and to any other applications that correspond to or claim priority to said Patents/Applications and/or Priority Documents, in whole or in part, and to any Letters Patents and similar protective rights granted on said other applications, and in

and to the right to claim any applicable priority rights arising from or required for said other applications under the terms of any applicable conventions, treaties, statutes, or regulations, including to all divisions, continuations, continuations-in-part, or renewals thereof, all Letters Patents which may be granted therefrom, all reexaminations, and all reissues or extensions of such patents; said other applications to be filed and issued in the name of ASSIGNEE or its designee insofar as permitted by applicable law;

AND, for the consideration aforesaid, ASSIGNOR agrees that it will make, execute, and deliver any and all other instruments in writing including any and all further application papers, affidavits, assignments and other documents, and will communicate to said ASSIGNEE, its successors and representatives all facts known to ASSIGNOR relating to said improvements and the history thereof and will testify in all legal proceedings and generally do all things which may be necessary or to secure to and vest in said ASSIGNEE, its successors or assigns the entire right, title, and interest in and to the said improvements, inventions, applications, Letters Patents, rights, titles, benefits, privileges and advantages assigned and conveyed, or intended so to be.

AND, furthermore, ASSIGNOR and ASSIGNEE do hereby further acknowledge the assignment of the rights, title, and interests described in this Assignment by affixing their signature below.

Date: 04 AUGUST 2021



CURIA GLOBAL, INC
(F/K/A ALBANY MOLECULAR RESEARCH, INC.)
Title: VP, DEPUTY GENERAL COUNSEL

STATE OF New York

Before me, a Notary Public in and for the State of New York, on this 4 day of August, 2021, personally appeared Benjamin Seidler, who, being duly sworn, signed and acknowledged the foregoing Assignment as his/her free act and deed.

Leah Ruth Threatte

NOTARY PUBLIC State of New York
County of Albany
NO OATH 6415175
My Commission Expires: MARCH 08 2025

(SEAL)



Date: 08/04/2021

HARMONY BIOSCIENCES, LLC
Title: President and CEO

STATE OF Pennsylvania

Before me, a Notary Public in and for the State of Pennsylvania, on this
4 day of August, 2021, personally appeared John C. Jacobs
_____, who, being duly sworn, signed and acknowledged the foregoing Assignment as his/her free act
and deed.

NOTARY PUBLIC Sharon E. Scott Goldbach

(SEAL)

My Commission Expires: 01/08/2023

Commonwealth of Pennsylvania - Notary Seal
Sharon E. Scott Goldbach, Notary Public
Montgomery County
My commission expires January 8, 2023
Commission number 1343622
Member, Pennsylvania Association of Notaries

[Signature Page to 646 PCT Assignment]

ANNEX A

Title	Country	Status	Provisional Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date
5-PYRIDOINDOLE SUBSTITUTED PYRIDOINDOLES	US	Expired	61/020,530	01/11/2008	N/A	N/A	N/A	N/A
PYRIDNONE- SUBSTITUTED PYRIDOINDOLES	US	Expired	61/048,677	04/29/2008	N/A	N/A	N/A	N/A

ANNEX B

TITLE	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES	PCT	National	PCT/US2009/030646	01/09/2009	WO/2009/089482	07/16/2009	N/A	N/A
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES	US	Issued	12/351,561	01/09/2009	US 2009/275590	11/05/2009	8,716,308	05/06/2014
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES	US	Issued	14/223,151	03/24/2014	US 2014/206696	7/24/2014	9,296,743	03/29/2016
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES	US	Issued	15/045,652	02/17/2016	US 2016/159798	6/9/2016	9,650,378	05/16/2017
[1-AZINONE] - SUBSTITUTED PYRIDOINDOLES AS MCH ANTOAGONISTS	AU	Issued	2009204048	1/9/2009	2009204048	7/16/2009	2009204048	11/14/2013
SUBSTITUTED PYRIDOINDOLES (1-AZINONE), PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS, AND USES THEREOF	BR	Issued	P10907122-9	1/9/2009	P10907122	7/14/2015	P10907122-9	4/16/2019
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS	CA	Issued	2,727,055	1/9/2009	2,727,055	7/16/2009	2,727,055	12/20/2016
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES	CN	Issued	200980105529.7	1/9/2009	101945872	1/12/2011	ZL200980105529.7	7/23/2014
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES	DE	Issued	12163813.4	1/9/2009			602009026369.2	8/27/2014
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES	EP	Issued	12163813.4	1/9/2009	2476680	7/18/2012	2476680	8/27/2014
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES	ES	Issued	12163813.4	1/9/2009			2476680	8/27/2014
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES	FR	Issued	12163813.4	1/9/2009			2476680	8/27/2014
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES	GB	Issued	12163813.4	1/9/2009			2476680	8/27/2014
TETRAHYDROPYRIDOINDOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF	IL	Issued	206594	1/9/2009	206594	5/31/2015	206594	9/1/2015

TITLE	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES	IT	Issued	12163813.4	1/9/2009			2476680	8/27/2014
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS	JP	Issued	2010-542381	1/9/2009	2011509937	3/31/2011	5501251	3/20/2014
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS	JP	Issued	2014-129417	06/24/2014	2016007620	01/18/2016	6382593	08/29/2018
1-AZINONE-SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS	KR	Issued	10-2010-7017685	1/9/2009	101614723	4/22/2016	10-1614723	4/18/2016
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS	MX	Issued	MX/a/2010/007430	1/9/2009	2010007430	12/21/2010	297875	4/4/2012
SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS	NZ	Issued	586120	1/9/2009	586120	7/27/2012	586120	11/5/2012
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS	SG	Published	2010047231	1/9/2009	162955	8/03/2010		
(1-AZINONE)-SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS	IN	Published	IN4937/CHENP/2010	8/09/2010	4937/CHENP/2010	12/02/2011		